(99) found that approximately 13% of NSCLC patients resistant to MET inhibitors had EGFR gene amplification, suggesting that EGFR bypass signaling pathway activation may be involved in resistance to MET inhibitors. The gene discussed is MET; the disease is non-small cell lung carcinoma.